Lilly Eli & Co (LLY): Endowment Inc Lilly , 10% owner of Lilly Eli & Co sold 220,000 shares on Jun 29, 2016. The Insider selling transaction was reported by the company on Jun 30, 2016 to the Securities and Exchange Commission. The shares were sold at $77.89 per share for a total value of $17129162 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 13, 2016, Melissa S Barnes (Chief Eth/Cmpl Ofcr & SVP, ERM) sold 992 shares at $73.77 per share price.On Jun 1, 2016, Endowment Inc Lilly (10% owner) sold 200,000 shares at $75.12 per share price.Also, On May 16, 2016, Jackson P Tai (director) purchased 1,080 shares at $75.75 per share price.On May 3, 2016, Donald A Zakrowski (Chief Accounting Officer) sold 1,600 shares at $75.99 per share price.
Eli Lilly and Co: On Wednesday, Jun 29, 2016 heightened volatility was witnessed in Eli Lilly and Co which led to swings in the share price. The shares opened for trading at $75.88 and hit $78.24 on the upside , eventually ending the session at $78.15, with a gain of 3.99% or 3 points. The heightened volatility saw the trading volume jump to 71,23,712 shares. The 52-week high of the share price is $92.85 and the company has a market cap of $86,265 M . The 52-week low of the share price is at $67.88.
On Jun 20, 2016, Eli Lilly and Co announced a cash dividend of $0.5100. The company’s management has announced Aug 11, 2016 as the ex-dividend date and fixed the record date on Aug 15, 2016. The payable date has been fixed on Sep 9, 2016.
Company has been under the radar of several Street Analysts.Eli Lilly and Co is Reiterated by Leerink Partners to Outperform and the brokerage firm has raised the Price Target to $ 101 from a previous price target of $96 .The Rating was issued on May 2, 2016.Eli Lilly and Co is Initiated by Societe Generale to Hold and the brokerage firm has set the Price Target at $78. The Rating was issued on Apr 6, 2016.
Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.